Structure-Based Design and Synthesis of 1H-pyrazolo[3,4-d]pyrimidin-4-amino Derivatives as Janus Kinase 3 Inhibitors

Publication date: Available online 4 April 2018
Source:Bioorganic & Medicinal Chemistry
Author(s): Yuan Yin, Cheng-Juan Chen, Ru-Nan Yu, Zhi-Jian Wang, Tian-Tai Zhang, Da-Yong Zhang
Janus kinases (JAKs) regulate various inflammatory and immune responses and are targets for the treatment of inflammatory and immune diseases. Here we report the discovery and optimization of 1H-pyrazolo[3,4-d]pyrimidin-4-amino as covalent JAK3 inhibitors that exploit a unique cysteine (Cys909) residue in JAK3. Our optimization study gave compound 12a, which exhibited potent JAK3 inhibitory activity (IC50 of 6.2 nM) as well as excellent JAK kinase selectivity (>60 fold). In cellular assay, 12a exhibited potent immunomodulating effect on IL-2-stimulated T cell proliferation (IC50 of 9.4 μM). Further, Compound 12a showed efficacy in delayed hypersensitivity assay. The data supports the further investigation of these compounds as novel JAKs inhibitors.

Graphical abstract

https://ift.tt/2Hdfv2S